# Anto Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anto-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.anto.bio
- Latest round: Seed (Jun 13, 2026)
- Investors on record: 1

## About

Based in San Francisco, US, founded in 2025, Anto Biosciences, Inc., provides advanced solutions for drug development through computational models. The company was co-founded by Arvid E. Gollwitzer and David de Gruijl. In June 2026, Anto Biosciences, Inc. raised a seed funding from Tekedia Capital.

Anto Biosciences specializes in creating a multimodal foundation model that computes the gut microbiome, aiming to predict drug toxicity and efficacy. By integrating various data types and minimizing noise, their technology enhances drug response accuracy. This enables clinical pharmacologists to align drug design with the microbiome, serving pharmaceutical companies and clinical researchers focused on drug development and personalized medicine globally, especially in North America and Europe.

Anto Biosciences generates revenue through partnerships with pharmaceutical companies and research institutions, structured as service agreements and collaborations. These arrangements allow access to Anto's computational models and datasets for a fee, likely varying based on the complexity of the analysis needed, ensuring tailored insights into drug efficacy across different populations.

The company plans to use the June 2026 funding to advance its development of computational models for the microbiome and support drug discovery and precision medicine applications.

## Funding rounds

- Seed, Jun 13, 2026 — Tekedia Capital

## Investors

- Tekedia Capital (https://capitalatlas.ai/funds/tekedia-capital) — Seed